par Di Leo, Angelo 
;Desmedt, Christine ;Bartlett, John M S;Piette, Fanny;Ejlertsen, Bent;Pritchard, Kathleen;Larsimont, Denis ;Poole, Christopher;Isola, Jorma;Earl, Helena;Mouridsen, Henning;O'Malley, Frances P;Cardoso, Fatima ;Tanner, Minna;Munro, Alison;Twelves, Chris J;Sotiriou, Christos ;Shepherd, Lois;Cameron, David A;Piccart-Gebhart, Martine ;Buyse, Marc;HER2/TOP2A Meta-analysis Study Group,
Référence Lancet oncology, 12, 12, page (1134-1142)
Publication Publié, 2011-11
;Desmedt, Christine ;Bartlett, John M S;Piette, Fanny;Ejlertsen, Bent;Pritchard, Kathleen;Larsimont, Denis ;Poole, Christopher;Isola, Jorma;Earl, Helena;Mouridsen, Henning;O'Malley, Frances P;Cardoso, Fatima ;Tanner, Minna;Munro, Alison;Twelves, Chris J;Sotiriou, Christos ;Shepherd, Lois;Cameron, David A;Piccart-Gebhart, Martine ;Buyse, Marc;HER2/TOP2A Meta-analysis Study Group, Référence Lancet oncology, 12, 12, page (1134-1142)
Publication Publié, 2011-11
Article révisé par les pairs
| Résumé : | Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer. |
